Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial
Fred Saad, Noel W. Clarke, Mototsugu Oya, Neal D. Shore, Giuseppe Procopio, João Daniel Guedes, Cagatay Arslan, Niven Mehra, Francis Parnis, Emma Brown, Friederike Schlürmann, Jae Young Joung, Mikio Sugimoto, Oliver Sartor, Yuzhen Liu, Christian Poehlein, Laura Barker, Paula Michelle del Rosario, Andrew J. Armstrong
Topics & Concepts
AbirateroneProstate cancerMedicinePlaceboOlaparibUrologyAbiraterone acetateInternal medicineOncologyDouble blindAndrogen deprivation therapyCancerAndrogen receptorPoly ADP ribose polymerasePolymeraseChemistryPathologyBiochemistryGeneAlternative medicineProstate Cancer Treatment and ResearchPARP inhibition in cancer therapyProstate Cancer Diagnosis and Treatment